The Food and Drug Administration (FDA) participated in the Culminating Activity and High-Level Media Forum of the Philippine Antimicrobial Awareness Week (PAAW) 2023 at Eastwood Richmonde Hotel, Quezon City on 24 November 2023.
The local theme for this year’s celebration is “Sama-samang Magtulungan Upang Antimicrobial Resistance ay Mapigilan” which highlights the importance of cross-sectoral collaboration through the One Health Approach. This is necessary due to the interrelatedness of human, animal health, plant production, food safety, and environment and the multifaceted issue of AMR requires a multisectoral approach to addressing it.
The FDA, as one of the stakeholders in this multisectoral partnership, reiterated and pledged its commitment to collaborate with other national government agencies, private sectors, and academe in the implementation of the Philippine Action Plan to Combat AMR through One Health Approach, as well as ensuring uninterrupted access to essential medicines of assured quality, and regulation and promotion of the rational use of medicines in the human and animal health sectors.
Director Irene V. Florentino-Fariñas, RPh, MD, MNSA, of the FDA-Policy and Planning Service gave a plenary talk entitled, “Combating AMR through Ensuring the Quality of Antimicrobials and Raising Consciousness on Counterfeit Medicines in the Philippines”. She discussed the causes of substandard and falsified pharmaceutical products and presented the data on the number of counterfeit drugs. Dr. Fariñas mentioned the FDA initiatives against counterfeit medicines towards prevention, detection, and response. Lastly, she highlighted the harmful impacts of counterfeit antimicrobials such as promoting AMR and the spread of drug-resistant infections and endangering the health of the general public.
The FDA remains deeply committed to the fight against AMR and steadfast in implementing its mandate to ensure the safety, efficacy, and quality of pharmaceuticals and other health products.
See more:-> https://bit.ly/3TlfQaQ